Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

Published:2016-03-29 Issue:18 Volume:7 Page:26259-26274
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kregel Steven¹,Chen James L.²,Tom Westin³,Krishnan Venkatesh³,Kach Jacob⁴,Brechka Hannah¹,Fessenden Tim B.¹,Isikbay Masis⁴³,Paner Gladell P.⁵,Szmulewitz Russell Z.⁴,Vander Griend Donald J.¹³

Affiliation:

1. Committee on Cancer Biology, The University of Chicago, Chicago, IL, USA

2. Department of Biomedical Informatics and Internal Medicine, The Ohio State University, Columbus, OH, USA

3. Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA

4. Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA

5. Department of Pathology, The University of Chicago, Chicago, IL, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway;Neoplasia;2024-11

2. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

3. Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells;Cancers;2024-08-24

4. Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation;Molecular Cancer Research;2024-05-31

5. Combination of miR-99b-5p and Enzalutamide or Abiraterone Synergizes the Suppression of EMT-Mediated Metastasis in Prostate Cancer;Cancers;2024-05-19